Format

Send to:

Choose Destination
See comment in PubMed Commons below
Breast Care (Basel). 2010;5(s1):16-21. Epub 2010 Apr 26.

Safety Profile and Clinical Recommendations for the Use of Lapatinib.

Author information

  • 1Gynäkologisch-onkologische Praxis Kreuzlingen, Switzerland.

Abstract

SUMMARY: The toxicity profile of agents blocking the epidermal growth factor receptor pathway excludes many of the severe side effects commonly observed with cytotoxic chemotherapy. Like other tyrosine kinase inhibitors, lapatinib is generally well tolerated. Lapatinib exhibits specific toxicities, the most common being diarrhea and rash, which are mostly mild to moderate in severity. Cardiac toxicity is rarely seen with lapatinib. Generally, lapatinib-associated toxicities are manageable.

PMID:
20847928
[PubMed]
PMCID:
PMC2931096
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for S. Karger AG, Basel, Switzerland Icon for PubMed Central
    Loading ...
    Write to the Help Desk